On 21 Aug 2021, Penpulimab injection (安尼可®) has officially begun its supply for hospitals and pharmacies across China. Penpulimab is the only new PD-1 monoclonal antibody worldwide that applies IgG1 subtype and modified by Fc segment. It is in-house developed by Akeso, Inc. (9926.HK) and in collaboration with Chia Tai Tianqing Pharmaceutical Group, a subsidiary of Sino Biopharmaceutical Limited (stock code: 1177.HK), for subsequent development and commercialization.
Many hospitals have prescribed Penpulimab injection for patients immediately. This marked an expanded treatment of relapsed or refractory (r/r) classic Hodgkin’s lymphoma (cHL) and Penpulimab injection officially starts to bring benefits to patients across the country.
Prof. Ma Jun, Director of Harbin Institute of Hematology and Tumor
Prescribing Penpulimab (安尼可®) for patients
Prof. Wu Depei, the First Affiliated Hospital of Soochow University
Prescribing Penpulimab (安尼可®) for patients
Prof. Huang Huiqiang, Affiliated Tumor Hospital of Sun Yat-sen University
Prescribing Penpulimab (安尼可®) for patients
Prof. Niu Ting, West China Hospital, Sichuan University
Prescribing Penpulimab (安尼可®) for patients
Prof. Liu Peng, Zhongshan Hospital Affiliated to Fudan University
Prescribing Penpulimab (安尼可®) for patients
Prof. Xu Wei, The First Affiliated Hospital of Nanjing Medical University
Prescribing Penpulimab (安尼可®) for patients
Prof. Shen Jianzhen, Union Hospital of Fujian Medical University
Prescribing Penpulimab (安尼可®) for patients
Prof. Zhou Keshu, Henan Cancer Hospital
Prescribing Penpulimab (安尼可®) for patients
Prof. Liang Rong, Xijing Hospital, Air Force Military Medical University
Prescribing Penpulimab (安尼可®) for patients
Penpulimab (安尼可®) is currently the only new PD-1 monoclonal antibody that applies IgG1 subtype and is modified by Fc segment, which has a lower antigen binding dissociation rate and a unique binding epitope as demonstrated by analysis on crystal structure. These features allow Penpulimab to effectively and continuously block PD-1/PD-L1 binding, thus differentiates it from other PD-1 products on the market, and may allow to more effectively enhance immunotherapeutic efficacy and reduce immune-related adverse reactions, as demonstrated by improved safety profile in clinical data.